Differences between primary peritoneal serous carcinoma and advanced serous ovarian carcinoma: a study based on the SEER database
Tóm tắt
This study aimed to compare clinical features and overall survival (OS) between patients with primary peritoneal serous carcinoma (PPSC) and those with advanced serous ovarian carcinoma (ASOC) and to identify prognostic factors. Patients diagnosed with PPSC and ASOC from 2010 to 2015 from the Surveillance, Epidemiology, and End Results (SEER) database were enrolled. Pearson’s chi-square test was used to compare clinical features. The primary endpoint was OS. The Kaplan–Meier method and log–rank test were used to perform the survival analysis. Propensity score matching was also conducted. Univariate, multivariate and subgroup analyses were performed using the Cox proportional hazards model. A total of 708 PPSC patients and 7610 ASOC patients were enrolled. The clinical features of PPSC patients were noticeably different from those of ASOC patients. The survival analysis showed that PPSC patients had poorer outcomes than ASOC patients. Even after the clinical features were balanced, PPSC patients still had poorer survival. Univariate and multivariate analyses indicated that older age, higher tumor grade and advanced American Joint Committee on Cancer stage were adverse prognostic factors in both groups, while surgery and chemotherapy were protective factors. A subgroup analysis demonstrated that most factors favored ASOC patients. The total distant metastasis rates of PPSC and ASOC were similar. Liver or lung metastasis was common, but bone and brain metastases were rare. A higher proportion of liver metastasis was observed in the ASOC group. The clinical features and survival outcomes between PPSC patients and ASOC patients are clearly different, and PPSC is more aggressive than ASOC.
Tài liệu tham khảo
Sahu SK, Agrawal S, Shirazi N, et al. Primary peritoneal papillary serous Cystadenocarcinoma - a rare malignancy. Chirurgia (Bucur). 2015;110:570–2.
Komiyama S, Nishijima Y, Kondo H, et al. Multicenter Clinicopathological study of high-grade serous carcinoma presenting as primary peritoneal carcinoma. Int J Gynecol Cancer. 2018;28:657–65.
Ozeki N, Hakiri S, Tateyama H, et al. Primary peritoneal carcinoma with late-phase pulmonary metastases: a case report. Surg Case Rep. 2019;5:194.
Chu CS, Menzin AW, Leonard DG, et al. Primary peritoneal carcinoma: a review of the literature. Obstet Gynecol Surv. 1999;54:323–35.
Duska LR, Kohn EC. The new classifications of ovarian, fallopian tube, and primary peritoneal cancer and their clinical implications. Ann Oncol. 2017;28:viii8–viii12.
Kossai M, Leary A, Scoazec JY, et al. Ovarian Cancer: a heterogeneous disease. Pathobiology. 2018;85:41–9.
Lisio MA, Fu L, Goyeneche A, et al. High-grade serous ovarian Cancer: basic sciences, Clinical and Therapeutic Standpoints. Int J Mol Sci. 2019;20:952.
Halperin R, Zehavi S, Langer R, et al. Primary peritoneal serous papillary carcinoma: a new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. Int J Gynecol Cancer. 2001;11:403–8.
Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: state of the science. Gynecol Oncol. 2020;156:715–25.
Gershenson DM. Low-grade serous carcinoma of the ovary or peritoneum. Ann Oncol. 2016;27(Suppl 1):i45–9.
Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines insights: ovarian Cancer, version 1.2019. J Natl Compr Cancer Netw. 2019;17:896–909.
Eltabbakh GH, Piver MS, Natarajan N, et al. Epidemiologic differences between women with extraovarian primary peritoneal carcinoma and women with epithelial ovarian cancer. Obstet Gynecol. 1998;91:254–9.
Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol. 2015;33:2675–82.
Gurkan D, Ceren Akin A, Sahin H, et al. Oncologic outcomes in patients undergoing maximal or optimal cytoreductive surgery for stage 3C serous ovarian, tubal or peritoneal carcinomas. J Obstet Gynaecol. 2020;40:551–7.
Ben-Baruch G, Sivan E, Moran O, et al. Primary peritoneal serous papillary carcinoma: a study of 25 cases and comparison with stage III-IV ovarian papillary serous carcinoma. Gynecol Oncol. 1996;60:393–6.
Bloss JD, Brady MF, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase II trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma-a gynecologic oncology group study. Gynecol Oncol. 2003;89:148–54.
Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying) - Linked To County Attributes - Total U.S., 1969–2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.
Eltabbakh GH, Werness BA, Piver S, et al. Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol. 1998;71:230–9.
Rei M, Raposo S, Figueiredo P, et al. Case Report: Borderline tumor and primary peritoneal carcinoma - a rare synchronism. F1000Res. 2019;8:1630.
Chao KC, Chen YJ, Juang CM, et al. Prognosis for advanced-stage primary peritoneal serous papillary carcinoma and serous ovarian cancer in Taiwan. Taiwan J Obstet Gynecol. 2013;52:81–4.
Kim J, Park EY, Kim O, et al. Cell origins of high-grade serous ovarian Cancer. Cancers (Basel). 2018;10:433.
Pentheroudakis G, Pavlidis N. Serous papillary peritoneal carcinoma: unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 2010;75:27–42.
Killackey MA, Davis AR. Papillary serous carcinoma of the peritoneal surface: matched-case comparison with papillary serous ovarian carcinoma. Gynecol Oncol. 1993;51:171–4.
Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053–64.
Katou S, Feist M, Raue W, et al. Inguinal lymph node metastasis of a primary serous papillary carcinoma of the peritoneum one year after CRS and HIPEC. Visc Med. 2018;34:307–9.
Deng K, Yang C, Tan Q, et al. Sites of distant metastases and overall survival in ovarian cancer: a study of 1481 patients. Gynecol Oncol. 2018;150:460–5.
Pakneshan S, Safarpour D, Tavassoli F, et al. Brain metastasis from ovarian cancer: a systematic review. J Neuro-Oncol. 2014;119:1–6.
Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53.
Enomoto T, Aoki D, Hattori K, et al. The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). Int J Gynecol Cancer. 2019;29:1043–9.
Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.
Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in patients with newly diagnosed advanced ovarian Cancer [J]. N Engl J Med. 2018;379(26):2495–505.
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.
Tan D, Sheng L, Yi QH. Correlation of PD-1/PD-L1 polymorphisms and expressions with clinicopathologic features and prognosis of ovarian cancer. Cancer Biomark. 2018;21:287–97.